Bristol-Myers Squibb receives positive CHMP opinion recommending approval of Opdivo
Bristol-Myers Squibb announced the CHMP of the European Medicines Agency has recommended the approval of Opdivo (nivolumab) for treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy. April 21, 2017